Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan-Dirk Studt

Showing results (11-20 of 58) with videos related to

Pageof 6
Sort By:
Journal of Medical Case Reports|March 15, 2022
Liver infarctions as the first manifestation of antiphospholipid antibody syndrome in pregnancy: a case reportClaudia Meloni, Cornelia Schreiber, Jan-Dirk Studt, et al.
Journal of Thrombosis and Haemostasis : JTH|February 7, 2021
COVID-19 patients often show high-titer non-platelet-activating anti-PF4/heparin IgG antibodiesJustine Brodard, Johanna A Kremer Hovinga, Pierre Fontana, et al.
British Journal of Haematology|March 5, 2003
ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13Gerhard Antoine, Klaus Zimmermann, Barbara Plaimauer, et al.
Swiss Medical Weekly|July 27, 2023
Recommendations for the use of andexanet alfa in the management of bleeding in patients on oral factor Xa inhibitors in Switzerland: Guideline from the Working Party Hemostasis of the Swiss Society of HematologyAnne Angelillo-Scherrer, Alessandro Casini, Jan-Dirk Studt, et al.
Thrombosis and Haemostasis|April 4, 2018
Risk Factors for Higher-than-Expected Residual Rivaroxaban Plasma Concentrations in Real-Life PatientsAlexander Kaserer, Andreas Schedler, Alexander Jetter, et al.
Seminars in Hematology|January 17, 2004
Plasma therapy in thrombotic thrombocytopenic purpura: review of the literature and the Bern experience in a subgroup of patients with severe acquired ADAMTS-13 deficiencyStefano Fontana, Johanna A Kremer Hovinga, Jan-Dirk Studt, et al.
Blood|February 21, 2004
Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpuraChristoph Klaus, Barbara Plaimauer, Jan-Dirk Studt, et al.
Sensors (Basel, Switzerland)|August 6, 2020
Point-of-Care Diagnostics in Coagulation ManagementSebastian D Sahli, Julian Rössler, David W Tscholl, et al.
Transfusion|September 25, 2024
Impact of elevated direct factor Xa inhibitor plasma levels on perioperative blood loss in patients undergoing urgent surgeryAlexander Mair, Sebastian D Sahli, Jan-Dirk Studt, et al.
Blood|September 16, 2004
Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobinJan-Dirk Studt, Johanna A Kremer Hovinga, Gerhard Antoine, et al.
Pageof 6

Showing results (11-20 of 58) with videos related to

Sort By:
Pageof 6
Journal of Medical Case Reports|March 15, 2022
Liver infarctions as the first manifestation of antiphospholipid antibody syndrome in pregnancy: a case reportClaudia Meloni, Cornelia Schreiber, Jan-Dirk Studt, et al.
Journal of Thrombosis and Haemostasis : JTH|February 7, 2021
COVID-19 patients often show high-titer non-platelet-activating anti-PF4/heparin IgG antibodiesJustine Brodard, Johanna A Kremer Hovinga, Pierre Fontana, et al.
British Journal of Haematology|March 5, 2003
ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13Gerhard Antoine, Klaus Zimmermann, Barbara Plaimauer, et al.
Swiss Medical Weekly|July 27, 2023
Recommendations for the use of andexanet alfa in the management of bleeding in patients on oral factor Xa inhibitors in Switzerland: Guideline from the Working Party Hemostasis of the Swiss Society of HematologyAnne Angelillo-Scherrer, Alessandro Casini, Jan-Dirk Studt, et al.
Thrombosis and Haemostasis|April 4, 2018
Risk Factors for Higher-than-Expected Residual Rivaroxaban Plasma Concentrations in Real-Life PatientsAlexander Kaserer, Andreas Schedler, Alexander Jetter, et al.
Seminars in Hematology|January 17, 2004
Plasma therapy in thrombotic thrombocytopenic purpura: review of the literature and the Bern experience in a subgroup of patients with severe acquired ADAMTS-13 deficiencyStefano Fontana, Johanna A Kremer Hovinga, Jan-Dirk Studt, et al.
Blood|February 21, 2004
Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpuraChristoph Klaus, Barbara Plaimauer, Jan-Dirk Studt, et al.
Sensors (Basel, Switzerland)|August 6, 2020
Point-of-Care Diagnostics in Coagulation ManagementSebastian D Sahli, Julian Rössler, David W Tscholl, et al.
Transfusion|September 25, 2024
Impact of elevated direct factor Xa inhibitor plasma levels on perioperative blood loss in patients undergoing urgent surgeryAlexander Mair, Sebastian D Sahli, Jan-Dirk Studt, et al.
Blood|September 16, 2004
Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobinJan-Dirk Studt, Johanna A Kremer Hovinga, Gerhard Antoine, et al.
Pageof 6